Every 10-Q that Serina Therapeutics (SER) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SER and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SER filings page.
Serina Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2026, compared with $0.1 million of grant revenue in the prior-year periods. Operating expenses rose as the company advanced its POZ polymer-based neurology pipeline.
For the six months ended June 30, 2026, Serina recorded a net loss of $13.3 million and used $11.3 million of net cash in operating activities. Cash and cash equivalents increased to $23.0 million, driven by equity financings including the March 2026 PIPE and ATM sales. Management states that existing cash is not expected to be sufficient for the next 12 months, and discloses substantial doubt about the company’s ability to continue as a going concern, indicating a need for additional capital to fund ongoing clinical development and operations.
Serina Therapeutics, Inc. reported a Q1 2026 net loss attributable to common stockholders of $6.9 million, or $0.58 per share, driven by research and development and general and administrative expenses totaling $6.3 million. Cash and cash equivalents were $24.5 million as of March 31, 2026, after using $4.6 million in operating cash during the quarter and raising equity capital through an at-the-market program and a March 2026 private placement. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months, even considering the additional $5.2 million gross proceeds from the April 2026 PIPE closing. The company continues to invest in its POZ-based pipeline, led by SER-252 for advanced Parkinson’s disease, and expects operating losses and cash needs to grow as clinical and preclinical activities expand.
Serina Therapeutics reported Q3 2025 results marked by losses and liquidity pressure. The company posted a net loss of $4.6 million for the quarter and $15.9 million for the nine months ended September 30, 2025, with no Q3 revenue and $0.1 million in grant revenue year to date. Cash and cash equivalents were $8.6 million as of September 30, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern.
Operating cash outflow was $11.9 million for the nine‑month period. To bolster liquidity, Serina raised capital through a $4.9 million private placement of Series A preferred stock, $2.2 million of net proceeds via an at‑the‑market program, and drew $5.0 million from a new unsecured convertible note that provides up to $20 million across clinical milestones. The FDA placed a clinical hold on the IND for SER‑252 on November 3, 2025, requesting additional information on an excipient. Shares outstanding were 10,664,064 as of November 10, 2025.